Ignite Creation Date:
2024-05-06 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05303558
Status:
COMPLETED
Last Update Posted:
2023-07-21
First Post:
2022-03-22
Brief Title:
A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
Sponsor:
Johnson Johnson International Singapore Pte Ltd
Organization:
Johnson Johnson International Singapore Pte Ltd
Study Overview
Official Title:
Real World Outcome Analysis for APAC High Risk Localized Prostate Cancer Patients Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACE
Brief Summary:
The purpose of this study is to evaluate the yearly conditional prostate-specific antigen PSA progression-free survival PFS probabilities in high-risk localized prostate cancer HR LPC participants following radical prostatectomy RP and perioperative hormonal therapies that is hormonal treatment before RP and or after RP over 5 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NOPRODPCR4002 | OTHER | Johnson Johnson International Singapore Pte Ltd | None |